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Tangeretin is a polymethoxylated flavone with multifaceted anticancer activity. In the 
present study, the metabolism and further antiproliferative activity of tangeretin was 
evaluated in the CYP1 expressing human breast cancer cell lines MCF7 and MDA–
MB–468 and the normal breast cell line MCF10A. Tangeretin was converted to 4ʹ OH 
tangeretin by recombinant CYP1 enzymes and in MCF7 and MDA–MB–468 cells. 
This metabolite was absent in MCF10A cells that did not express CYP1 enzymes. 
Tangeretin exhibited submicromolar IC50 (0.25±0.15 μM) in MDA–MB–468 cells, 
whereas it was less active in MCF7 cells (13.5±0.8 μM) and completely inactive in 
MCF10A cells (>100 μM). In MDA–MB–468 cells that were coincubated with the 
CYP1 inhibitor acacetin, an approximately 70–fold increase was noted in the IC50 
(18±1.6 μM) of tangeretin. In the presence of the CYP1 inhibitor acacetin, the 
conversion of tangeretin to 4ʹ OH tangeretin was significantly reduced in MDA–MB–
468 cells (2.55±0.19 μM vs. 6.33±0.12 μM). The mechanism of antiproliferative 
action involved cell cycle arrest at the G1 phase for MCF7 and MDA–MB–468 cells, 
whereas the cell cycle of MCF10A cells was unaffected by 10 μM of tangeretin 
treatment for 24 and/or 48 h. Tangeretin was further shown to induce CYP1 enzyme 
activity and CYP1A1/CYP1B1 protein expression in MCF7 and MDA–MB–468 
cells. Taken collectively, the results suggest that tangeretin inhibits the proliferation 
of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and 
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Flavonoids are polyphenolic molecules with multiple modes of biological action. 
Their cancer preventative and/or anticancer activity has been attributed to various 
different mechanisms including the induction of apoptosis, the modulation of cell 
signaling, the inhibition of the cell cycle and notably the process of mitosis, the 
induction and/or modulation of autophagy, the inhibition of invasion and metastasis 
and the interaction with Reactive Oxygen Species (ROS) and ROS signaling (Johnson 
and de Mejia, 2013; Qi et al., 2015; Hsieh et al., 2016; Cheng et al., 2015; Salmela et 
al., 2012; Sosa et al., 2013; Kim et al., 2015; Jo et al., 2015; Li et al., 2013; 
Doleckova et al., 2012). In addition to the aforementioned biological activities, the 
interactions of natural dietary flavonoids with xenobiotic phase I metabolizing 
enzymes, notably the cytochrome P450 CYP1 enzymes, have been investigated by 
recent studies (Androutsopoulos et al., 2008; Androutsopoulos et al., 2009a; 
Androutsopoulos et al., 2009b; Androutsopoulos et al., 2009c; Androutsopoulos et al., 
2009d; Androutsopoulos et al., 2010; Androutsopoulos and Spandidos 2013; 
Androutsopoulos and Tsatsakis 2014). CYP1 enzymes have been shown to participate 
in the metabolic activation of pro–carcinogens to their ultimate carcinogenic 
derivatives, whereas recently an anti–inflammatory role of these enzymes was 
demonstrated in Cyp1a1/1a2/1b1 (⁻/⁻) C57BL/6J triple knockout mice compared with 
C57BL/6J wild-type mice, via the regulation of the metabolism of arachidonic acid 
lipid mediators of inflammation (Nebert and Dalton 2006; Divanovic et al., 2013). 
With regard to dietary flavonoids, a cancer therapeutic effect of these compounds has 
been demonstrated in breast and liver cancer cells via their intracellular metabolism 
by CYP1 enzymes (Androutsopoulos et al., 2008; Androutsopoulos et al., 2009a; 
Androutsopoulos et al., 2009b; Androutsopoulos et al., 2009d). These compounds are 
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oxidized to their corresponding hydroxylated derivatives via aromatic hydroxylation 
and/or demethylation reactions occurring at the B and/or A rings of the polyphenolic 
moiety (Androutsopoulos et al., 2008; Androutsopoulos et al., 2009a; 
Androutsopoulos et al., 2009b; Androutsopoulos et al., 2009d; Androutsopoulos and 
Spandidos 2013; Androutsopoulos and Tsatsakis 2014). The resulting metabolites 
inhibit cancer cell growth at equivalent and/or higher levels compared with the 
corresponding parent compounds (Androutsopoulos et al., 2008; Androutsopoulos et 
al., 2009a; Androutsopoulos et al., 2009b; Androutsopoulos et al., 2009d). It is 
important to note that synergistic effects resulting from the combined action of the 
parent flavonoid compound and the CYP1–metabolite have been documented, thus 
accounting for the overall antiproliferative activity (Androutsopoulos and Spandidos 
2013).   
Tangeretin is a fully methoxylated flavone that is present in the peel of citrus fruits 
and has demonstrated anticancer activity via biologically distinct mechanisms of 
action. Tangeretin causes G2/M arrest and induces apoptosis in glioma cells by 
modulating PTEN and the cell cycle regulating genes, namely D1 and cdc2, whereas 
in human meningioma cells this compound induces apoptosis by enhanced 
phosphorylation of glycogen synthase 3 β (GSK3β) and inhibition of the Wnt5/β–
catenin pathway (Ma et al., 2016; Das et al., 2015). Tangeretin was further shown to 
inhibit breast cancer formation in a rat model of DMBA–induced mammary 
carcinogenesis via p53/p21 upregulation and inhibition of metastasis by 
downregulation of MMP2, MMP9 and VEGF expression (Arivazhagan and 
Sorimuthu Pillai 2014; Lakshmi and Subramanian 2014). Despite these promising 
studies, the metabolism of tangeretin by CYP1 enzymes remains poorly defined. With 
the exception of a previous study by Walle and Walle that examined tangeretin 
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metabolism by recombinant CYP enzymes and the hepatic liver S9 fraction, there is 
no evidence in the literature regarding the association of CYP1 enzymes and the 
cancer therapeutic effect of tangeretin (Walle and Walle, 2007). In the present study, 
the metabolism of tangeretin was investigated in the CYP1 expressing breast cancer 
cell lines MCF7 and MDA–MB–468 and the normal breast cell line MCF10A. The 
data suggest that tangeretin is metabolized to one major conversion product by a 
demethylation reaction at the B ring that in turn inhibits cancer cell growth.  
 
 
2. Materials and Methods 
2.1 Chemicals and antibodies 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), propidium 
iodide (PI), 7-ethoxyresorufin, resorufin, α-napthoflavone, acacetin, tissue culture 
reagents and media, Western blotting lysis buffer and DTT were purchased from 
Sigma Aldrich (St Louis, MO, USA). Tangeretin and 4ʹ OH tangeretin were 
purchased from Apin chemicals (Abingdon, UK). Western blotting reagents were 
from Bio-Rad (Berkeley, CA, USA). The polyclonal antibody for CYP1A1 was from 
Daiichi Pure Chemicals (Gentest corporation, MA, USA), whereas the monoclonal 
antibodies for CYP1B1 from Auvation Limited (Glasgow, Scotland, UK), and for β-
actin from Cell signaling (Leiden, Netherlands). Secondary antibodies for western 
blotting were from Santa Cruz Biotechnology (Dallas, TX, USA).  
 
2.2 Cell culture  
MCF7 and MDA–MB–468 cells were maintained in RPMI with glutamine (2 mM) 
containing 10% heat-inactivated FBS and penicillin/streptomycin. MDA–MB–468 
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cells were grown in RPMI without phenol red, whereas MCF10A cells were grown in 
DMEM:F12 with insulin (10 μg/ml), hydrocortisone (500 ng/ml), EGF (20 ng/ml), 
10% FBS and 2 mM glutamine. The cells were grown in a humidified incubator at 37 
C in 5% CO2 /95% air and passaged every 3 to 4 days using trypsin EDTA (0.25% 
v/v).  
 
2.3 Tangeretin metabolism  
Recombinant CYP1 enzymes and control microsomes were incubated with 10 μM of 
tangeretin at 37 °C in the presence of NADPH (0.5 mM), MgCl2 (0.5 mM) and 
phosphate buffer (20 mM). Time points were obtained at 0, 5, 10, 15, 20 and 25 min 
intervals. The reactions were terminated by addition of equal volumes of methanol 
and acetic acid at a 100:1 ratio. The samples were centrifuged at 3,500 g for 20 min at 
4 C and the supernatants were analyzed by reversed phase HPLC.  
 
2.4 HPLC analysis 
The methodology has been described in detail in previous publications 
(Androutsopoulos et al., 2009a, Androutsopoulos et al., 2008). A Luna C18 4.6 x 150 
mm 5 µ column was used and the mobile phase consisted of solvents A and B. 
Solvent A comprised 1% acetonitrile and 0.5% acetic acid in H2O and solvent B 4% 
acetonitrile and 0.5% acetic acid in CH3OH. The following gradient was used: 60% 
solvent A and 40% solvent B at time=0 min and 10% solvent A and 90% solvent B at 
time=10 min. The final conditions were maintained for 1 min and the composition of 
the solvents was adjusted to the initial conditions with 8 min remaining for column 
equilibration after each run. The detection of tangeretin concentration was monitored 
using a Waters Series 200 UV detector (Waters, Hertfordshire, UK) at 327 nm. The 
concentration of tangeretin was estimated by a calibration curve covering the range of 
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0.05–10 M. The assay was carried out at 37 C and the flow rate was 1 ml/min. The 
average recovery for tangeretin was 93% and the retention time using the 
aforementioned parameters was 18.1 min.  
 
2.5 LC-MS analysis 
Mass spectrometry analysis of tangeretin was conducted on an Agilent 1100 Series 
LC/MSD Trap XCT systems with a photodiode array detector. The separation of 
tangeretin was conducted using a Phenomenex Luna 5μ C18 (250×4.6mm) column 
and the following solvents: (A) water, (B) methanol and (C) acetonitrile. The initial 
conditions were as follows: 59% solvent A, 40% solvent B and 1% solvent C. The 
analytical column temperature was 40˚C and the flow rate was 0.8 ml/min. A total of 
50 μL of sample solution were analyzed. A linear gradient was initiated immediately 
on the start of the analysis with solvent B rising to 90% and solvent C rising to 4% 
over 15 min. These solvent compositions were held for 2min before returning to the 
initial conditions (using a flow rate of 0.8ml/min). A re-equilibration time of 8 min 
was allowed between each sample analysis. The photodiode array detector was set at 
330 nm. The LC flow was controlled from the photodiode array detector into the mass 
spectrometer without stream splitting. The MS determination was acquired in 
electrospray ionisation (ESI) positive mode. Molecular ions ([M+H]+) were detected 
in the range of 200–500 using an auto–MS mode. Nitrogen was used as the nebulizing 
gas at 60 psi and as drying gas with the flow rate of 10 L/min at 350˚C. The MS data 
were analyzed using LC/MSD Trap software 5.3. The Retention time (Rt) of 




2.6 MTT assay  
MCF7, MDA–MB–468 and MCF10A cells (1 x 10
4
 cells/ml) were seeded in 96-well 
plates and the antiproliferative effect of tangeretin was examined as described 
previously (Androutsopoulos et al., 2008). Inhibition experiments were conducted in 
the presence of 0.5-1 μM α-napthoflavone and/or acacetin.  
 
2.7 FACS analysis 
MDA–MB–468 and MCF10A were grown in T25 flasks at approximately 30% 
confluence. The cells were treated with tangeretin at concentrations of 10, 30 and 50 
μM in the presence and/or absence of CYP1 inhibitors (0.5–1 μM) for 24 and 48 h. 
The cells were subsequently washed with PBS, removed by trypsin/EDTA and 
centrifuged at 3,500 rpm for 5 min. The cells were fixed in 70% ethanol for at least 24 
h at –20 °C. The ethanol was removed and PBS containing PI (50 μg/ml) and RNAse 
(100 μg/ml) was added to the cells that were incubated further for 30 min at 37 °C. 
Flow cytometry was conducted using a Beckman Coulter flow cytometer at PMT4 
and at least 10,000 events were acquired for analysis. The Multicycle analysis 2.0 
Software was used for the determination of the cell cycle corresponding to the 
samples.    
 
2.8 Western blotting  
MCF7, MDA–MB–468 and MCF10A cells were cultured in T25 flasks at a density of 
5×10
5
 cells/ml. The cells were washed once with PBS and lysed with 100 μl of lysis 
buffer that contained protease inhibitor cocktail and DL-dithiothreitol (DTT, 1 mM). 
The cells were subsequently sonicated on ice for 5 min and centrifuged at 13,000 rpm 
at 4 °C for 15 min. The protein concentration required for the experiment was 
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adjusted to 0.7 mg/ml for each sample, and the protein extract was mixed with sample 
buffer that contained 5% mercaptoethanol at a 1:1 ratio. The samples were loaded on 
an acrylamide gel containing 10% acrylamide for the resolving gel and 5% 
acrylamide for the stacking gel and electrophoresis was carried out for 1 h at 120 V. 
Following electrophoresis, the proteins were transferred by wet blotting to a PVDF 
membrane. The membrane was incubated in 10% milk/0.05% TBST at room 
temperature for 1 h by continuous shaking in order to block the non specific binding 
sites. The primary antibodies against CYP1A1, CYP1B1 and β-actin were added to 
the membrane at 1:800, 1:500 and 1: 3,000 dilutions, respectively at 4 °C overnight. 
The membrane was subsequently washed three times with 0.05% TBST and incubated 
with the secondary antibody against HRP (1:2,000) diluted in 1% milk/0.05% TBST 
at room temperature for 1.5 h. The membrane was finally exposed to ECL reagents, 
and the expression profile of the proteins was developed on film.   
 
2.9 EROD assay 
MCF7 and/or MDA–MB–468 cells (2×105 cells/ml) were plated in 96–well plates. The 
cells were incubated at 37˚C, 5% CO2 for 24h and subsequently tangeretin was added at a 
concentration range of 0.1, 0.3, 1, 3, 10, 30 and 100 μM, respectively. The induction of 
EROD activity was assayed at the 6, 9 and 24 h time points and at shorter time points, 
namely 15,30 and 60 min. Following the end of the treatment period, the medium was 
aspirated and the cells were washed with PBS thrice. A total of 200 μl of medium 
containing 5μM 7–ethoxyresorufin and 1.5mM salicylamide to inhibit conjugating 
enzymes were added to each well, and the plates were further incubated for 1 h. The 
reactions were terminated by addition of 150 μl of ice–cold methanol to the wells, 
followed by centrifugation at 3,500 rpm at 4˚C for 15min. Subsequently, 200 μl of 
supernatant were transferred to a clear bottom black 96–well plate and the amount of 
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resorufin produced was measured using a fluorescence plate reader with an excitation and 
emission wavelength at 530nm and 590nm, respectively. The data were analyzed, 
following subtraction of the blank fluorescence that contained resorufin alone from each 
sample reading. The concentration of resorufin was measured using a calibration curve. 
The units of enzyme activity were expressed as concentration of resorufin formed per 
time, per amount of cells.  
 
2.10 Statistical analysis 
The data were presented as the mean of at least three independent measurements and 
were analyzed by the paired t–test, the unpaired t–test and the One-Way analysis of 




3.1 Recombinant CYP1 enzymes metabolize tangeretin 
The metabolism of tangeretin by recombinant CYP1 enzymes was examined by LC–
MS analysis. A main metabolite was formed, which was assigned as TP1. The mass 
spectrum of TP1 indicated the presence of an ion at 359.1, whereas the ion that 
corresponded to the parent compound tangeretin was 373.1 (Fig. 1B). CYP1A1 was 
shown to be the predominant catalyst of tangeretin metabolism compared with 
CYP1B1 and CYP1A2 following 30 min of enzyme incubation with the compound 
(Fig. 1A). CYP1B1 was a weak metabolizer of tangeretin and produced a minor 
quantity of TP1 (Fig. 1A). The order of the overall metabolism was as follows: 
CYP1A1>CYP1A2>CYP1B1 (Fig. 1A). The difference in the molecular weights of 
tangeretin and TP1 (373–359=14), as determined by their molecular ions suggested 
that a de–methoxylation occurred in the initial structure of tangeretin (Fig. 1C). The  
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comparison with an authentic standard of 4ʹ OH tangeretin revealed that this 
compound had the same retention time as TP1, thus confirming the identity of this 





Figure 1. Cytochrome P450 CYP1–mediated metabolism of tangeretin. Recombinant 
CYP1 enzymes were incubated with tangeretin (10 μM) and samples were collected at 
0, 5, 10, 15, 20, 25 and 30 min time intervals as described in Material and Methods. 
Control incubations contained control microsomes with empty vector. (A) Schematic 
bioconversion of tangeretin to the metabolite 4ʹ OH tangeretin and/or TP1. (B) The 
concentration of tangeretin and its metabolite TP1 was measured by LC-MS analysis 




3.2 CYP1 enzymes metabolize tangeretin in MCF7 and MDA–MB–468 human breast 
cancer cells 
The human breast cancer cell lines MCF7 and MDA–MB–468 have been employed in 
previous studies for the investigation of the CYP1–mediated metabolism and 
bioactivation of dietary flavonoids (Androutsopoulos et al., 2008). In the present 
study, the metabolism of tangeretin was examined in the aforementioned cell lines. A 
main metabolite that matched the retention time of TP1 was identified following 
incubation of tangeretin with MDA–MB–468 and/or MCF7 cells for 24 h (Fig. 2A). 
This metabolite was absent in MCF10A cell extracts (Fig. 2A,B). The reduction of the 
parent compound was higher in MDA–MB–468 compared with MCF7 cells following 
24 h of incubation (Fig. 2A, B). The metabolism of tangeretin to TP1 was enhanced in 
MCF7 cells that were pretreated with TCDD (10 nM) for 24 h, whereas the 
metabolism of this compound in MDA–MB–468 cells was evident from 1 h of 
incubation and gradually increased at the 3, 6 and 9 h time points, respectively (Fig. 
2C,D). LC–MS was further used in order to add insight in the identification of the 
primary metabolite of tangeretin. The LC chromatogram of the assay matched that 
noted from the HPLC experiments with regard to the retention time of the 
compounds, whereas the MS analysis revealed that TP1 exhibited a molecular mass of 
359 (Fig. 3A,B). TP1 was identified as 4ʹ OH tangeretin by comparison with an 
authentic standard. Thus, the main metabolite of tangeretin in the CYP1 expressing 





Figure 2. HPLC analysis of tangeretin following incubation with the human breast 
cell lines MCF7, MDA–MB–468 and MCF10A. A starting concentration of 10 μM 
was used and the metabolism was investigated at 0, 3, 6, 9 and 24 h time points by 
HPLC as described in materials and methods. The experiments were conducted at 
least 3 times and error bars indicate STDEV of the mean. (A) HPLC chromatograms 
of tangeretin in the 3 breast cell lines at 0 (grey color) and 24 h (blue color) time 
points. (B) Measurement of the concentration of the parent compound and the 
metabolite TP1 in the 3 cell lines. (C) HPLC chromatograms of tangeretin in MCF7 
cells, MCF7 pretreated for 24 h with 10 nM TCDD, and MDA–MB–468  cells at 0 
(grey color), 1 (blue color), 3 (green color), 6 (red color) and 9 (pink color) h time 
points. (D) Quantification of the concentration of tangeretin and the metabolite TP1 at 
the 6 and 9 h time points.  
 
   
3.3 Tangeretin is bioactivated in the CYP1–expressing cell lines MDA–MB–468 and 
MCF7 
Previous studies have demonstrated that MDA–MB–468 cell constitutively express 
CYP1 enzymes compared with MCF10A cells that express little or no CYP1 protein, 
whereas MCF7 cells express minimal amounts of CYP1 enzyme levels that are 
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increased following pretreatment with a CYP1 inducer (Androutsopoulos et al., 2008; 
Androutsopoulos et al., 2009). The present study utilized the aforementioned cell lines 
to investigate the antiproliferative activity of tangeretin. This compound was 
considerably active in MDA–MB–468 cells and indicated a submicromolar IC50 
(0.25±0.15 μM), whereas it demonstrated minimal antiproliferative activity in 
MCF10A cells (>100 μM) (Fig. 4A). In MCF7 cells the IC50 of tangeretin (13.5± 0.8 
μM, Fig. 4B) was considerably higher compared with MDA–MB–468 cells, whereas 
pretreatment of the cells with TCDD (10 nM) for 24 h decreased the overall IC50 
value to a minor extent (9.7± 0.5 μM, Fig. 4B) compared with the difference noted in 
the aforementioned 2 cell lines. Despite this minor decrease, the results were 
significantly different between the two different types of treatments (MCF7 +– 
TCDD)(Fig. 4B).  
The cytotoxicty of tangeretin in MDA–MB–468 cells was investigated in the presence 
of the CYP1 inhibitors acacetin and α–napthoflavone (Fig. 4C). The IC50 of 
tangeretin was considerably increased from 0.25±0.15 μM to 18±1.6 μM μM in the 
presence of the CYP1 inhibitor acacetin (Fig. 4C). Similar results were noted for the 
use of α–napthoflavone as a CYP1 inhibitor. The cytotoxicity of the metabolite TP1 
was evaluated in the 3 breast cell lines and it was found that this compound was more 
active in MDA–MB–468 compared with MCF7 and MCF10A cells (Fig. 4D). MCF7 
cell viability was reduced to a higher extent by 5, 10 and 20 μM of TP1 compared 
with that noted for MCF10A cells (P<0.05, Fig. 4D). 
In addition, metabolic studies revealed that in the presence of the CYP1 inhibitors the 
conversion of 4ʹ OH tangeretin from tangeretin was substantially reduced both in 
MDA–MB–468 and MCF7 cells (Fig. 4E, F). Specifically, an approximately 3–fold 
decrease (2.55±0.19 μM vs. 6.33±0.12 μM) was noted for the conversion of TP1 by  
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Figure 3. LC-MS analysis of the metabolism of tangeretin in MDA–MB–468 and 
MCF10A cells. (A) LC chromatograms of the incubation of tangeretin with the 
MDA–MB–468 and MCF10A cell lines at various time points (24, 96 h).  (B)  Mass 
spectrum of TP1 in the cell line incubates. 
 
 
tangeretin, in the presence of the CYP1 inhibitors compared with the incubation of the 
parent compound with MDA–MB–468 cells alone (Fig. 4F). 
The antiproliferative effect of tangeretin on the 2 human breast cancer cell lines and 
the normal breast cell line was further investigated by flow cytometry analysis. 
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Treatment of MDA–MB–468 cells with tangeretin (10 μM) for 24 and 48 h resulted in 
a significant increase of the population of cells in the G1 phase (Fig. 5A–D, K, 
P<0.05). This increase was accompanied by a concomitant significant decrease in the 
percentage of cells in the S phase in the tangeretin–treated (Fig. 5A–D, K, P<0.05) 
samples. The effect of tangeretin in MDA–MB–468 cells was partially reversible as in 
the presence of the CYP1 inhibitor acacetin a significant decrease in the population of 
the cells at G1 phase was noted compared with the single treatment of tangeretin (Fig. 
5A,B,D,K, P<0.05).    
 MCF7 cells appeared less sensitive to tangeretin treatment and although significant 
differences were noted between the control and the treated samples, these were 
somewhat lower in magnitude compared to those noted in MDA–MB–468 cells (Fig. 
5 E–G, L). In contrast to the breast cancer cell lines, MCF10A cells were unaffected 
by tangeretin treatment (10 μM) at either 24 and/or 48 h (Fig. 5H–J, M).  
 
 
3.4 Tangeretin induces CYP1 enzyme expression in MCF7 and MDA–MB–468 cells 
The initial experiments in MCF7 cells revealed metabolism of tangeretin in the 
absence of TCDD pretreatment to the conversion product 4ʹ OH tangeretin (Fig. 2A). 
In addition, the previous study on nobiletin by Surichan and colleagues demonstrated 
that this structurally similar polymethoxyflavone was capable of inducing its own 
metabolism in MCF7 cells via induction of CYP1 enzyme expression (Surichan et al., 
2012). Based on this evidence, the induction of CYP1 enzyme expression by 
tangeretin was investigated in MCF7 and MDA–MB–468 cells following treatment 
with this compound for 24 h. CYP1 enzyme activity was significantly increased in 






Figure 4. The bioactivation of tangeretin in the CYP1 expressing cell lines MDA–
MB–468 and MCF7. Cell viability was measured using the MTT assay as determined 
in the materials and methods section. The experiments were conducted at least 3 times 
and error bars indicate STDEV of the mean. Cell survival plots indicating the IC50 
determination of tangeretin in (A) MDA–MB–468 and MCF10A cells and (B) MCF7 
cells and MCF7 cells pretreated for 24 with 10 nM TCDD, and (C) MDA–MB–468 
and MCF10A cells in the presence of the CYP1 inhibitor acacetin (0.5 μM). Similar 
results were obtained when the CYP1 inhibitor α–napthoflavone was used. (D) The 
inhibition of cell viability in MDA–MB–468, MCF10A and MCF7 cells by the 
tangeretin–metabolite TP1. TP1 was tested at concentrations of 5, 10 and 20 μM. * 
indicate significant differences of the reduction in cell viability between the MCF10A 
and the MCF7 cells (P<0.05). (E) The metabolism of tangeretin in MDA–MB–468 
cells in the presence and/or absence of the CYP1 inhibitor acacetin (0.5 μM). HPLC 
chromatogram of MDA–MB–468 cell incubation with tangeretin, in the presence 
and/or absence of acacetin (0.5 μM) for 24 h. (F) Quantification of the concentration 
of the compounds tangeretin and TP1 in MDA–MB–468 cells, in the presence and/or 
absence of the CYP1 inhibitor acacetin (0.5 μM). 
 
 
tangeretin (Fig. 6A,B). In MCF7 cells, CYP1 enzyme activity indicated a substantial 
increase at 3 μM that peaked at 10 and 30 μM of compound treatment compared with 
control cells (Fig. 6B). In contrast to MCF7, MDA–MB–468 cells exhibited a basal 
expression of CYP1 enzyme activity that was increased considerably following 
treatment with 3, 10 and 30 μM of tangeretin (Fig. 6A). This increase was similar 
among all treatments, as opposed to MCF7 cells where a dose response was noted for 
the concentration range 0-10 μM (Fig. 6B). The maximum activity in MDA–MB–468 
cells was nearly half of that noted for 10 nM of TCDD (152±3.7 vs. 225±12.1 
pmol/min/10
6
 cells, Fig. 6A). A similar trend was noted for MCF7 cells, with the 
exception that the induction caused by TCDD was considerably higher compared with 
that caused by 30 μM of tangeretin treatment (53±1.4 vs. 21±1.1 pmol/min/10
6
 cells, 
Fig. 6B). At the highest concentration of 30 μM of tangeretin, an approximately 3–
fold and 20–fold increase in CYP1 enzyme activity was observed compared with  
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Figure 5. Cell cycle analysis of tangeretin in the 3 human breast cell lines MCF7, 
MDA–MB–468 and MCF10A at 24 and 48 h time points. Cell cycle histograms of 
(A) control MDA–MB–468 cells (B) tangeretin–treated (48 h) MDA–MB–468 cells 
(C) tangeretin–treated (24 h) MDA–MB–468 cells (D) tangeretin–treated (48 h) 
MDA–MB–468 cells in the presence of the CYP1 inhibitor acacetin (0.5 μM) (E) 
control MCF7 cells (F) tangeretin–treated (24 h) MCF7 cells (G) tangeretin–treated 
(48 h) MCF7 cells (H) control MCF10A cells (I) tangeretin–treated (24 h) MCF10A 
cells (J) tangeretin–treated (48 h) MCF10A cells. Distribution of the cells in each 
phase of the cell cycle. (K) MDA–MB–468 cells (L) MCF7 cells (M) MCF10A cells. 
The experiments were conducted at least 3 times and error bars indicate STDEV of 
the mean. * indicate significant differences in the cell population of each phase 
between the control and the treated samples (P<0.05). * indicate significant 
differences in the cell population of each phase between the tangeretin–treated 
samples in the presence and/or absence of the CYP1 inhibitor acacetin (0.5 μM) 
(P<0.05). 
 
control cells, for MDA–MB–468 and MCF7 cells, respectively (152±3.7 vs. 55±5.4 
pmol/min/10
6
 cells, 21±1.1 vs. 0.9±0.05 vs. pmol/min/10
6
 cells Fig. 6A,B). 
The induction of CYP1 enzyme expression by tangeretin was further monitored by 
western immunoblotting. Tangeretin induced CYP1A1 protein in a dose dependent 
manner in MDA–MB–468 and MCF7 cells (3–30 μM) (Fig. 6C,D). The induction of 
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CYP1A1 protein at 3 μM of tangeretin treatment was lesser in MCF7 compared with 
MDA–MB–468 cells, whereas the induction of CYP1A1 in MDA–MB–468 cells was 
approximately half of that noted for TCDD, as opposed to MCF7 cells (Fig. 6C,D). 
With regard to MCF7 cells, the induction of CYP1A1 by tangeretin was lower than 
half of that noted for TCDD (Fig. 6D). In contrast to CYP1A1, tangeretin induced 
CYP1B1 protein expression at minimal levels in MDA–MB–468 cells compared with 
DMSO control samples (Fig. 6C).  
 
4. Discussion 
Tangeretin is a flavonoid that has demonstrated various types of anticancer activities. 
In the present study, the interactions of cytochrome P450 CYP1 enzymes with 
tangeretin were investigated. CYP1 enzymes metabolized tangeretin to the conversion 
product TP1 that was identified as 4ʹOH tangeretin. CYP1A1 was the main metabolic 
catalyst followed by CYP1A2 and CYP1B1. In addition, tangeretin was metabolized 
to 4ʹOH tangeretin in the human breast cancer cell lines MDA–MB–468 and MCF7, 
whereas this conversion was absent in the normal breast cell line MCF10A. 4ʹOH 
tangeretin exhibited higher antiproliferative activity compared with tangeretin that 
resulted in the bioactivation of tangeretin in the CYP1 expressing breast cancer cell 
lines, as demonstrated by metabolic, cell cycle and cytotoxicity studies in the presence 
of the CYP1 inhibitors acacetin and α-napthoflavone. Furthermore, tangeretin was 
capable of inducing CYP1 enzyme activity and CYP1A1/CYP1B1 enzyme expression 
in MDA–MB–468 and MCF7 cells. The data suggest that CYP1 enzymes can activate 





Figure 6. Tangeretin induces CYP1 activity and CYP1A1/CYP1B1 protein in human 
breast cancer cells. Tangeretin (3, 10, 30 μM) was incubated with MCF7 and MDA–
MB–468 cells for 24 h and CYP1 activity was measured by the EROD assay as 
described in materials and methods. (A) MDA–MB–468 cells (B) MCF7 cells (C) 
Western immunoblotting of CYP1A1/CYP1B1 protein expression in MDA–MB–468 
cells pretreated with Tangeretin (3, 10, 30 μM) for 24 h and (D) Western 
immunoblotting of CYP1A1/CYP1B1 protein expression in MCF7 cells pretreated 
with tangeretin (3, 10, 30 μM) for 24 h. TCDD was used as a positive control at 10 
nM. 
 
The metabolism of tangeretin by CYP1 enzymes was investigated concisely in an 
early study conducted by Walle and Walle in 2007 (Walle and Walle, 2007). The 
authors examined the metabolism of a range of methoxylated flavones, including 
mono–, di–, tri– and fully methoxylated compounds, by human liver microsomes and 
recombinant CYP3A4, CYP2C9, CYP2D6 and CYP1A1/CYP1A2 enzymes (Walle 
and Walle, 2007). In accordance with the present study, CYP1A1 was the 
predominant catalyst of all compounds investigated with the exception of 5,7,4ʹ 
trimethoxyflavone that was metabolized slightly faster by CYP1A2 compared with 
CYP1A1. Oxidative demethylation was demonstrated as the rate–limiting metabolic 
reaction for fully methylated flavones, which is in agreement with the present study 
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and our earlier report that investigated the metabolism of the fully methylated flavone 
nobiletin by CYP1 enzymes (Walle and Walle 2007; Surichan et al., 2012). However, 
Walle and Walle did not examine the metabolism of tangeretin by CYP1B1 and did 
not identify the corresponding conversion products as opposed to the present study. In 
an earlier study conducted by Breinholt and colleagues, the identity of the CYP1A2, 
CYP3A4, CYP2D6 and CYP2C9–catalyzed metabolites of tangeretin was verified by 
LC/MS (Breinholt et al., 2003). The major metabolic routes involved one 
demethylation step at the 4ʹ position of the B ring and 2 demethylation steps at the 5 
and 6 position of the A ring that yielded the corresponding 4ʹ hydroxy tangeretin and 
5,6 dihydroxy tangeretin, respectively (Breinholt et al., 2003). In addition, the 
demethylation at the 4ʹ position of the B ring has been previously reported as the main 
CYP1–mediated metabolic reaction for the structurally similar flavones nobiletin and 
eupatorin (Surichan et al., 2012; Androutsopoulos et al., 2008). Although the present 
study demonstrated that the major conversion product of CYP1A1 and CYP1B1 
metabolism of tangeretin was 4ʹ hydroxy tangeretin, the presence of additional 
metabolites was not evident notably in the human breast cancer cell lines MCF7 and 
MDA–MB–468. The possible explanations for this outcome include the reduced 
levels of CYP1A1/CYP1B1 enzyme activity compared with the recombinant CYP1 
enzymes.  
The metabolism of tangeretin to 4ʹ hydroxy tangeretin enhanced the antiproliferative 
activity of the parent compound, as determined by cell viability and cell metabolism 
studies. Furthermore, it is important to note that the mechanism of action involved G1 
arrest of MDA–MB–468 cells that was reversed in the presence of the CYP1 
inhibitors acacetin and α-napthoflavone. The data are in agreement with previous 
reports that demonstrated cytostatic effects of tangeretin in colon cancer, breast cancer 
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and yeast cells (Pan et al., 2002; Morley et al., 2007; Chong et al., 2013; Arivazhagan 
and Sorimuthu Pillai 2014). Induction of G1 arrest in combination with upregulation 
of p53/p21 and downregulation of p–Rb and cyclin D1 were caused by tangeretin 
treatment in rat breast cancer cells and human colon cancer cells, respectively 
(Arivazhagan and Sorimuthu Pillai 2014; Pan et al., 2002). Moreover, the induction of 
apoptosis, the inhibition of VEGF activity and the downregulation of MMP–2 and 
MMP–9 are additional modes of action that have been reported for tangeretin (He et 
al., 2015; Charoensinphon et al., 2013; Arivazhagan and Sorimuthu Pillai 2014). The 
present study provides additional evidence regarding the antiproliferative activity of 
the CYP1–metabolite 4ʹ hydroxy tangeretin. This novel mechanism of action that 
includes CYP1–mediated bioactivation of tangeretin to 4ʹ hydroxy tangeretin may 
apply for other types of cancer cells, such as colon cancer cells that express active 
CYP1 enzymes. 
With regard to the potency of tangeretin in inhibiting the proliferation of human 
breast cancer cells, this compound exhibited high activity in MDA–MB–468 
compared with MCF7 cells. By contrast, MCF10A cells were notably unaffected as 
the IC50 of tangeretin noted in this cell line was higher than 100 μM. Tangeretin 
exhibited an activation factor of approximately 72–fold in MDA–MB–468 cells 
compared with MDA–MB–468 cells that were treated with tangeretin and CYP1 
inhibitors (18 μM/0.25 μM). A similar trend has been previously demonstrated for the 
flavonoids sinensetin, genkwanin and eupatorin in our earlier reports 
(Androutsopoulos et al., 2009d; Androutsopoulos et al., 2008). These compounds 
exhibited IC50 values for MDA–MB–468 cells of 0.2, 1.6 and 0.5 μM, respectively, 
whereas in MCF10A cells they were considerably less active (65, 75 and 50 μM, 
respectively). In the presence of the CYP1 inhibitor acacetin, the IC50 values of 
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sinensetin, eupatorin and genkwanin were considerably increased (from 0.2 to 13.5 
μM for sinensetin, from 0.5 to 15 μM for eupatorin and from 1.6 to 12.5 μM for 
genkwanin) (Androutsopoulos et al., 2009d; Androutsopoulos et al., 2008). The data 
reported in the present study are in agreement with the aforementioned studies and 
suggest that the degree of methoxylation in the flavone moiety enhances the 
antiproliferative activity of these compounds in MDA–MB–468 cells due to 
cytochrome P450 CYP1–metabolism. This is verified by the observation that 
sinensetin and tangeretin that are both penta–methoxylated flavones exhibited 
submicromolar IC50 values with similar activation factors in the presence of CYP1 
inhibitors (68–fold vs. 72–fold).  
In addition, the data indicated that tangeretin induced CYP1 enzyme activity and 
CYP1 enzyme expression in MCF7 and MDA–MB–468 human breast cancer cells. 
CYP1A and CYP2B enzyme activities and CYP1A and CYP2B enzyme expression 
were increased by tangeretin treatment in rat liver tissues, as demonstrated by an early 
study by Canivenc–Lavier et al. (Canivenc–Lavier et al. 1996). Additional studies 
have documented CYP1 inductive effects by the structurally similar flavones 
eupatorin, cirsiliol, eupatorin–5–methyl ether and nobiletin in human breast cancer 
cells at similar concentrations to those used for tangeretin in the current report 
(Androutsopoulos et al., 2009c, Androutsopoulos and Tsatsakis 2014, Surichan et al., 
2012). Hydroxylated and monomethoxylated flavones such as quercetin and 
diosmetin, respectively, have also been shown to induce CYP1A1 mRNA and 
CYP1A enzyme activity via direct binding to the AhR in MCF7 breast cancer cells 
(Ciolino et al., 1999; Ciolino et al., 1998). It was suggested that the lipophilicity of 
these natural compounds that is determined by their methoxy substitutions affected 
their binding to the AhR and consequently the induction of CYP1 enzyme activity.  
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Figure 7. Putative metabolic pathway indicating the bioactivation of tangeretin in 
cancer cells. Tangeretin is obtained by nutritional sources and can inhibit the cell 
cycle arrest of cancer cells at the G1 phase by metabolism to the conversion product 
4ʹ OH tangeretin.  
 
 
Our preliminary analysis suggests that tangeretin induces the expression of the AhR 
and its translocation to the nuclei of MCF7 cells (data not shown). It is important to 
note that the induction of CYP1B1 protein by tangeretin is shown for the first time as 
previous studies were mainly focused on the interactions of CYP1A1 and CYP1A 
enzymes with dietary flavones (Canivenc–Lavier et al. 1996; Ciolino et al., 1999; 
Ciolino et al., 1998).  
In conclusion, the present study investigated the anticancer effects of tangeretin with 
regard to CYP1–mediated metabolism, CYP1–enzyme induction and inhibition of 
cellular proliferation of human breast cancer cells. The data demonstrate that 
tangeretin is activated in human breast cancer cells due to CYP1–mediated conversion 
to the metabolite 4ʹ hydroxy tangeretin that in turn results in G1 arrest of the cells 
(Fig. 7). These effects were absent in normal breast cells that do not express CYP1 
enzymes. The findings suggest that tangeretin could possess therapeutic implications 
in breast cancer cells that express active CYP1 enzymes (Fig. 7). In conclusion, 
tangeretin may be considered as a selective CYP1–activated natural product that can 
be further evaluated for its cancer therapeutic efficacy in vivo. 
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